SSA
ITCI icon

Schonfeld Strategic Advisors’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-382,233
Closed -$50.4M – 2716
2025
Q1 		$50.4M Buy
382,233
+361,693
+1,761% +$45.1M 0.3% 35
2024
Q4 		$1.72M Sell
20,540
-197
-0.9% -$16.2K 0.01% 892
2024
Q3 		$1.52M Sell
20,737
-113,717
-85% -$8.55M 0.01% 1009
2024
Q2 		$9.21M Buy
134,454
+110,036
+451% +$7.63M 0.06% 371
2024
Q1 		$1.69M Sell
24,418
-141,703
-85% -$9.74M 0.01% 1050
2023
Q4 		$11.9M Buy
+166,121
New +$9.56M 0.08% 300
2022
Q4 		– Sell
-32,071
Closed -$1.49M – 3084
2022
Q3 		$1.49M Sell
32,071
-31,130
-49% -$1.63M 0.01% 1025
2022
Q2 		$3.61M Sell
63,201
-34,724
-35% -$1.97M 0.04% 561
2022
Q1 		$5.99M Buy
97,925
+76,210
+351% +$3.96M 0.05% 391
2021
Q4 		$1.14M Buy
+21,715
New +$912K 0.01% 874
2017
Q4 		– Sell
-131,980
Closed -$2.08M – 911
2017
Q3 		$2.08M Buy
+131,980
New +$1.94M 0.19% 154
2017
Q2 		– Sell
-30,989
Closed -$504K – 803
2017
Q1 		$504K Buy
+30,989
New +$448K 0.05% 365
2016
Q3 		– Sell
-11,871
Closed -$460K – 573
2016
Q2 		$460K Buy
+11,871
New +$427K 0.1% 240

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Schonfeld Strategic Advisors's ITCI Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 382,233 shares — an estimated $50.4M sold.

Schonfeld Strategic Advisors first reported a position in ITCI in Q2 2016 and held it in 13 quarters. The position peaked at $50.4M in Q1 2025. 3 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 382,233 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $50.4M.
  • Schonfeld Strategic Advisors first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 13 quarters.
  • Schonfeld Strategic Advisors's Intra-Cellular Therapies Inc. position peaked at $50.4M in Q1 2025.
  • 3 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.